Articles tagged with: Maintenance Therapy
Perhaps the title of this column more appropriately should be “Life After CRD,” since I’ve now completed 24 cycles of Kyprolis (carfilzomib), Revlimid (lenalidomide), and dexamethasone (Decadron), commonly referred to as CRD, as part of a clinical trial for newly diagnosed patients.
However, since dexamethasone seemed to be the predominate source of my side effects, and because I liked the play on words, I went with the title as shown.
So, I’ve completed the clinical trial, I’ve reached stringent complete response, and I’ve won …
While I am not so much a creature of habit, my Wednesday afternoon activities over the last three years have been pretty much chiseled in stone.
At around noon on a typical Wednesday, I drop everything that I’m doing, jump into my car, drive across the Kimberling City Bridge that sits perched 30 feet above beautiful Table Rock Lake, and then wind my way through the rolling Ozark hills and picturesque hollows toward the nationally known tourist and entertainment small city of Branson, Missouri.
Upon arrival at my destination, I …
Results of a recent Spanish study suggest that elderly multiple myeloma patients who receive Velcade plus thalidomide or Velcade plus prednisone as maintenance therapy achieve deeper responses following initial therapy with Velcade-based treatment regimens.
In addition, elderly myeloma patients who receive Velcade plus thalidomide as maintenance therapy may achieve better treatment outcomes and longer survival rates than patients who receive Velcade plus prednisone as maintenance therapy.
“In our trial, VT [Velcade plus thalidomide] was slightly superior to VP [Velcade plus prednisone] in response rate and outcome, but the differences didn’t …
The National Comprehensive Cancer Network (NCCN) has updated its guidelines for the treatment of multiple myeloma, and the new guidelines will be interpreted by many as a vote of confidence for Revlimid maintenance therapy.
The NCCN guidelines are followed closely by physicians and by many U.S. health insurance companies, which frequently use them when making reimbursement decisions about different cancer treatments.
The guidelines are comprised of recommendations based on the results of recent clinical trials and ongoing scientific research. A panel of specialists within the myeloma field is responsible for …
Results of a recent, small German study show that donor stem cell transplantation followed by Revlimid maintenance therapy may be feasible in heavily pretreated relapsed or refractory multiple myeloma patients.
“For younger and fit patients, [donor] stem cell transplantation followed by maintenance therapy with [Revlimid] is a reasonable treatment option for patients who have already relapsed [after an autologous stem cell transplant],” said Dr. Nicolaus Kröger of the University Hospital Hamburg-Eppendorf in Germany and lead investigator of the study.
Dr. Philip McCarthy of the Roswell Park Cancer Institute in Buffalo, …